Diogenx
Preclinical biotech developing regenerative protein therapies for type 1 diabetes, aimed at restoring insulin-producing beta cells
Highlights
- New on EvolcAdded 2026-11-02
About Diogenx
DiogenX is a preclinical-stage biotech company developing first-in-class recombinant proteins for the treatment of type 1 diabetes. Its lead program, DGX-01, modulates the Wnt/β-catenin signalling pathway to regenerate insulin-producing pancreatic beta cells, and it is currently in IND-enabling studies.
The company's work is based on pancreatic beta cell regeneration research by Patrick Collombat, who is a co-founder. The therapies are intended for patients with type 1 diabetes. The company is supported by a consortium of investors that includes Boehringer Ingelheim Venture Fund, Roche Venture Fund, Eli Lilly and Company, Omnes, Sunstone Capital, T1D Fund and AdBio partners.
DiogenX was founded in 2019 and is headquartered in Marseille, France, with research labs in Nice, France. Benjamin Charles is CEO. The executive team includes a Chief Medical Officer and a Chief Development Officer, and the board includes representatives of its investors.
Product: DGX-01, a preclinical recombinant protein therapy for type 1 diabetes that regenerates insulin-producing beta cells.
Jobs at Diogenx
Leadership
- Jean-Pascal Tranié · Co-FounderSource: company website
- Patrick Collombat · PhD, co-founderSource: company website
- Benjamin Charles · CEO, co-founder, member of the BoardSource: company website
More biotech & pharma companies
Discngine
Scientific software and custom IT services for life science research and early drug discovery teamsNew on EvolcDNA Script
Benchtop enzymatic DNA synthesis system for labs that need ready-to-use oligos in-house, overnightNew on EvolcRemote-friendlyDomes Pharma
Veterinary pharmaceutical group making animal health products for vets, pharmacies and pet owners in France and abroadNew on EvolcEdelris
Drug discovery CRO offering compound libraries, screening and medicinal chemistry to pharma and biotech teamsNew on EvolcEligo Bioscience
In vivo microbiome gene-editing technologies for developing targeted therapies for human diseaseNew on EvolcEmka Technologies
Telemetry, ECG and physiological monitoring systems and software for preclinical research labs working with rodents and large animalsNew on EvolcRemote-friendly
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Backend
- PHPHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerx-powered-by
- Response headerx-powered-by
- Response headerx-powered-by
Content management
- ElementorHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.